Third Harmonic Bio, Inc. (THRD)
- Previous Close
11.28 - Open
11.33 - Bid 11.41 x 200
- Ask 11.52 x 200
- Day's Range
10.96 - 11.60 - 52 Week Range
4.06 - 12.42 - Volume
201,472 - Avg. Volume
133,819 - Market Cap (intraday)
465.366M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.78 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.55
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
www.thirdharmonicbio.comRecent News: THRD
Performance Overview: THRD
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THRD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THRD
Valuation Measures
Market Cap
465.77M
Enterprise Value
200.66M
Trailing P/E
13.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.53%
Return on Equity (ttm)
-11.04%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.82M
Diluted EPS (ttm)
-0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
269.07M
Total Debt/Equity (mrq)
1.47%
Levered Free Cash Flow (ttm)
-18.04M
Research Analysis: THRD
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell